Successful treatment of refractory Schnitzler syndrome with anakinra: comment on the article by Hawkins et al.
Victor Manuel
VM
Martinez-Taboada
Ana
A
Fontalba
Ricardo
R
Blanco
Jose Luis
JL
Fernández-Luna
D000328:Adult; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D006801:Humans; D053590:Interleukin 1 Receptor Antagonist Protein; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use*; D017472:Receptors, Interleukin-1 / Q000037:antagonists & inhibitors*; D019873:Schnitzler Syndrome / Q000188:drug therapy*; D012795:Sialoglycoproteins / Q000627:therapeutic use*; D016896:Treatment Outcome
D018501:Antirheumatic Agents; C507763:IL1RN protein, human; D053590:Interleukin 1 Receptor Antagonist Protein; D017472:Receptors, Interleukin-1; D012795:Sialoglycoproteins; D008727:Methotrexate